Maintained renin-angiotensin-aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study

By sjmartinez • May 3, 2024

Rastogi A, Pollack CV Jr, Sánchez Lázaro IJ, Lesén E, Arnold M, Franzén S, Allum A, Hernández I, Murohara T, Kanda E. Maintained renin-angiotensin-aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study. Clin Kidney J. 2024 Mar 25;17(5):sfae083. doi: 10.1093/ckj/sfae083. PMID: 38699484; PMCID: PMC11062025.

Tags: Chronic kidney disease, heart failure, hyperkalaemia, Nephrology, Publications, renin–angiotensin–aldosterone system inhibitor, sodium zirconium cyclosilicate

Clinical characteristics and CKD care delivery in African American and American Indian or Alaska Native patients: A real-world cohort study

Mayhand KN, Alicic RZ, Kornowske LM, Jones CR, Daratha KB, Reynolds CL, Nicholas SB, Thorpe RJ Jr, Bui AAT, Norris KC, Tuttle KR. Clinical characteristics[...]

The End Kidney Deaths Act-Reply

Mueller TF, Matamoros MA, Danovitch GM. The End Kidney Deaths Act-Reply. JAMA. 2025 Jul 21. doi: 10.1001/jama.2025.8243. Epub ahead of print. PMID: 40690250.

Population risk predictors of major adverse kidney events attributed to focal segmental glomerulosclerosis from the CURE-CKD registry

Nicholas SB, Kornowske LM, Jones CR, Daratha KB, Alicic RZ, Reynolds CL, Neumiller JJ, Bensink ME, Gong W, Norris KC, Tuttle KR. Population risk predictors[...]